Пятилетний анализ эффективности вакцинации пневмококковой инфекции у пациентов с хронической обструктивной болезнью легких

This study was aimed at analysis of 5-year clinical efficacy and pharmacoeconomic effectiveness of conjugate pneumococcal vaccine in patients with chronic obstructive pulmonary disease (COPD). Methods. Male patients with COPD (n = 394) were involved in the study. Primary endpoints were changes in MMRC score, FEV1, number of exacerbations and hospitalizations, and a rate of pneumonia. The BODE index was calculated. Drug therapy of all patients was analyzed. 13-valent conjugate pneumococcal vaccine PCV13 and 23-valent polysaccharide vaccine PPV23 were used for vaccination. Results. Vaccination with PCV13 resulted in improvement in dyspnea and lung function both for short-term and 5-year follow-up. Therefore, PCV13 could be considered as a part of the basic therapy along with bronchodilators. Vaccination with PCV-13 could reduce risk of unfavorable events in the course of COPD and improve the patients’ survival. Conclusion. Vaccination with PCV13 in patients with COPD could reduce number of exacerbations, incidence of pneumonia, and the need in healthcare resources due to maintaining the effect during 4 years. Budget savings could reach 409.9 million rubles per a year.